FDA warning letter to Wholesale Peptide names Prostamax and gonadorelin
Short answer · as of 2026-10-05
DOCUMENTED. FDA posted a warning letter on June 23, 2026 (dated June 17) to Wholesale Peptide of Brooksville, FL, saying its Prostamax and gonadorelin products are unapproved new drugs. The letter is FDA's allegation; the firm had 15 working days to respond.
Attribution: Compiled from the warning letter as posted on FDA's website, read on October 5, 2026. We have not seen a company response. This is an archive entry added after publication of the later 2026 letters.
Allegations in government documents and in reports by others are theirs, not findings by us. Verify against the linked sources. Disclaimer.
By Peptide Industry Gossip · Observed · Published
What happened
- On June 23, 2026, FDA posted a warning letter dated June 17, 2026 to Wholesale Peptide, Brooksville, FL.
- The letter says FDA reviewed the firm's website in May 2026 and names Prostamax and gonadorelin. The products' labeling carried wording such as “research use only” and “not for human consumption.”
- FDA says the website's claims establish the products are intended as drugs. It describes claims about prostate inflammation, bladder control, prostatitis, and testosterone production and testes function, plus references to prostate cancer cell growth. It says the research-only wording does not change that.
- The letter gave the firm 15 working days from receipt to describe the steps it had taken to correct the violations.
What we can verify
- FDA posted the letter on June 23, 2026; it remained on FDA's site when we read it on Oct. 5, 2026.
- The letter cites sections 201(g)(1), 201(p), 301(d) and 505(a) of the FD&C Act and the 15-working-day response window.
What remains unknown
- Whether the firm responded, removed the listed products, or faced further action.
- Whether the site is still operating; we did not check it.
Timeline
| Date / time | Event |
|---|---|
| 2026-06-17 | FDA issues a warning letter to Wholesale Peptide (Brooksville, FL). |
| 2026-06-23 | FDA posts the letter. It gives the firm 15 working days from receipt to respond. |
Receipts
- FDA warning letter: Wholesale Peptide (June 17, 2026) · captured 2026-10-05 · tier 1
- FDA warning letters table (checked Oct. 5, 2026) · captured 2026-10-05 · tier 1
Company response
No company response located as of the publish date.
Why people care
The claims FDA quotes concern prostate and testosterone-related effects, not weight loss. That shows the letters are not limited to GLP-1-class products, and that FDA applies the same research-only reasoning to other peptides.
New to warning letters? Does an FDA warning letter mean a company is shut down?
Corrections and update log
No corrections or updates. Request a correction.
Related vendor records
Related stories
DOCUMENTED. FDA posted warning letters on Sept. 1, 2026 (dated Aug. 24) to five peptide sellers, stating that products sold as “research use only” are unapproved new drugs. The letters are FDA’s allegations; each firm was told to respond within 15 business days.
REPORTED. FDA’s page confirms a July 23-24, 2026 advisory committee meeting on seven peptides; outlets report the panel supported six of them (including BPC-157) for the 503A bulks list and rejected one, although FDA’s own briefing document proposed that none of the seven be included. The votes are nonbinding and a formal rule would be needed before pharmacies could compound them.
DOCUMENTED. FDA posted warning letters on Apr. 7, 2026 (dated Mar. 31) to five peptide sellers, citing unapproved new drug violations; all five letters also name bacteriostatic water sold alongside the peptides. The letters are FDA’s allegations; each firm had 15 working days to respond.